2Q Revenues: $5.6 billion (+10%)
2Q Earnings: $1.2 billion (+13%)
YTD Revenues: $11 billion (+10%)
YTD Earnings: $2.5 billion (+12%)
Comments: Pharmaceutical sales were $4.7 billion in the quarter, up 11%, driven by higher sales of Prevnar (+22%), Protonix (+25%), Enbrel (+37%), Nutrition products (+19%), and Zosyn (+17%). This increase was offset by lower sales of Zoton and Inderal LA due to generic competition. In the quarter, Lybrel and Torisel received FDA approval. 2Q results include charges of $49.8 million related to the company's productivity initiatives.